ALX ONCOLOGY HOLDINGS INC
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
ALXO$1.11-13.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(35,898) | $(56,703) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 5,192 | 7,352 |
| Depreciation and amortization | 236 | 402 |
| Non-cash lease costs | 737 | 933 |
| Net accretion of discounts on investments | (540) | (837) |
| Accretion of term loan discount and issuance costs | 134 | 136 |
| Loss on early debt extinguishment | 904 | — |
| Gain on lease termination | (2,592) | — |
| Lease impairment charge | — | 3,175 |
| Loss on disposal of fixed assets | 246 | — |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | 929 | 652 |
| Other assets | 307 | (433) |
| Accounts payable | (1,975) | 409 |
| Payable and accrued liabilities due to related party | — | (109) |
| Accrued expenses and other current liabilities | (1,652) | (2,019) |
| Other non-current liabilities | (733) | (1,027) |
| Net cash used in operating activities | (34,705) | (48,069) |
| Investing activities | ||
| Purchase of investments | (130,240) | (41,177) |
| Maturities of investments | 31,750 | 91,245 |
| Purchase of property and equipment | (67) | (107) |
| Proceeds from sale of property and equipment | 44 | — |
| Net cash (used in) provided by investing activities | (98,513) | 49,961 |
| Financing activities | ||
| Proceeds from equity offering | 150,000 | — |
| Payments of issuance costs related to equity offering | (9,627) | — |
| Proceeds from ATM offering, net of commissions | 11 | 372 |
| Proceeds from exercise of stock options under equity incentive plan | 743 | — |
| Proceeds from issuance of common stock under employee stock purchase plan | 31 | 15 |
| Proceeds from exercise of pre-funded warrants | 6 | — |
| Principal payments on finance leases | (543) | (544) |
| Principal payments on term loan | (2,609) | — |
| Payments for early debt extinguishment | (8,176) | — |
| Proceeds from issuance of term loan | 10,000 | — |
| Payments of debt issuance costs | (104) | — |
| Net cash provided by (used in) financing activities | 139,732 | (157) |
| Net increase in cash, cash equivalents and restricted cash | 6,514 | 1,735 |
| Cash, cash equivalents and restricted cash at beginning of year | 16,439 | 17,633 |
| Cash, cash equivalents and restricted cash at end of period | $22,953 | $19,368 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Purchase of property and equipment in accounts payable and accrued expenses | $26 | $1,060 |
| Debt issuance costs in accounts payable and accrued expenses | $193 | $— |
| Right-of-use asset acquired under operating leases | $168 | $— |
| Reconciliation of cash and cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $22,687 | $19,302 |
| Restricted cash (included in prepaid expenses and other current assets) | 66 | — |
| Restricted cash (included in other assets) | 200 | 66 |
| Total cash, cash equivalents and restricted cash | $22,953 | $19,368 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.